Value202020212022202320242025TTMSelling/general/admin expenses44.17 M71.1 M90.31 M116.5 M125.83 M119.8 M119.8 MResearch & development150.41 M229.81 M419.98 M435.07 M466.31 M388.86 M388.86 MOperating income-136.58 M-267.85 M-458.16 M-515.29 M-534.26 M440.99 M-243.57 MNon-Operating Income, Total2.35 M1.32 M24.56 M83.93 M95.61 M58.39 M58.39 MInterest expense, net of interest capitalized———————Non-Operating Income, excl. Interest Expenses2.35 M1.28 M40.59 M49.83 M80.37 M30.09 M30.09 MUnusual income/expense—42 K-16.02 M34.1 M15.24 M28.3 M28.3 MPretax income138.94 M270.5 M493.81 M614.86 M629.88 M499.38 M499.38 MEquity in earnings—1.32 M11.08 M15.63 M00—Taxes—————0—Non-controlling/minority interest———————After tax other income/expense———————Net income before discontinued operations-134.23 M-267.89 M-474.19 M-481.19 M-519.02 M412.69 M210.05 MDiscontinued operations———————Net income-134.23 M-267.89 M-474.19 M-481.19 M-519.02 M412.69 M210.05 MDilution adjustment———————Preferred dividends———————Diluted net income available to common stockholders134.23 M267.89 M474.19 M481.19 M519.02 M412.69 M412.69 MBasic earnings per share (Basic EPS)——-6.16-5.42-5.25-3.81-3.81Diluted earnings per share (Diluted EPS)——-6.16-5.42-5.25-3.81-3.81Average basic shares outstanding——76.97 M88.77 M98.85 M108.38 M421.33 MDiluted shares outstanding——76.97 M88.77 M98.85 M108.38 M421.33 MEBITDA20.16 M-31.14 M—————EBIT13.86 M-38.04 M—————Cost of revenue00—————Other cost of goods sold———————Depreciation & amortization (cash flow)6.3 M6.9 M7.6 M9 M10.3 M9.77 M9.77 M
Intellia Therapeutics Inc
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases.
The CRISPR gene editing system was originally invented by Jennifer Doudna, one of Intellia's scientific founders, and Virginijus Šikšnys. The company has entered into a number of different research and development collaborations with leading and emerging biotechnology companies including Novartis, Regeneron, Avencell, SparingVision, Kyverna, and ONK Therapeutics.
Intellia has two in vivo programs in ongoing clinical trials. NTLA-2001 is an investigational CRISPR therapy candidate for the treatment for ATTR amyloidosis currently in Phase 1 studies.